Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis

Peter A. Fasching, Siddhartha Yadav, Chunling Hu, Marius Wunderle, Lothar Häberle, Steven N. Hart, Matthias Rübner, Eric C. Polley, Kun Y. Lee, Rohan D. Gnanaolivu, Peyman Hadji, Hanna Hübner, Hans Tesch, Johannes Ettl, Friedrich Overkamp, Michael P. Lux, Arif B. Ekici, Bernhard Volz, Sabrina Uhrig, Diana LüftnerMarkus Wallwiener, Volkmar Müller, Erik Belleville, Michael Untch, Hans Christian Kolberg, Matthias W. Beckmann, André Reis, Arndt Hartmann, Wolfgang Janni, Pauline Wimberger, Florin Andrei Taran, Tanja N. Fehm, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Andreas D. Hartkopf, Fergus J. Couch

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE: Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome. PATIENTS AND METHODS: Germline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes. The frequencies of mutations in known BC predisposition genes were compared with results from a prospective registry of patients with nonmetastatic BC sequenced using the same QIAseq method and with public reference controls. Associations between mutation status and tumor characteristics, progression-free survival, and overall survival were assessed. RESULTS: Germline mutations in 12 established BC predisposition genes (including BRCA1 and BRCA2) were detected in 271 (10.4%) patients. A mutation in BRCA1 or BRCA2 was seen in 129 patients (5.0%). BRCA1 mutation carriers had a higher proportion of brain metastasis (27.1%) compared with nonmutation carriers (12.8%). Mutations were significantly enriched in PRAEGNANT patients with mBC compared with patients with nonmetastatic BC (10.4% v 6.6%, P < .01). Mutations did not significantly modify progression-free survival or overall survival for patients with mBC. CONCLUSION: Multigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in BRCA1/2 and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.

Original languageEnglish (US)
Pages (from-to)1619-1630
Number of pages12
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume39
Issue number15
DOIs
StatePublished - May 20 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis'. Together they form a unique fingerprint.

Cite this